Please use this identifier to cite or link to this item:
https://hdl.handle.net/1959.11/30649
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ooi, Esther M M | en |
dc.contributor.author | Watts, Gerald F | en |
dc.contributor.author | Chan, Dick C | en |
dc.contributor.author | Chen, Meifania M | en |
dc.contributor.author | Nestel, Paul J | en |
dc.contributor.author | Sviridov, Dmitri | en |
dc.contributor.author | Barrett, P Hugh R | en |
dc.date.accessioned | 2021-05-26T00:42:45Z | - |
dc.date.available | 2021-05-26T00:42:45Z | - |
dc.date.issued | 2008-08 | - |
dc.identifier.citation | Diabetes Care, 31(8), p. 1656-1661 | en |
dc.identifier.issn | 1935-5548 | en |
dc.identifier.issn | 0149-5992 | en |
dc.identifier.uri | https://hdl.handle.net/1959.11/30649 | - |
dc.description.abstract | <p><b>OBJECTIVE</b> - Dysregulated apolipoprotein (apo)C-III metabolism may account for hypertriglyceridemia and increased cardiovascular risk in the metabolic syndrome. This study investigated the dose-dependent effect of rosuvastatin on VLDL apoC-III transport in men with the metabolic syndrome.</p><p> <b>RESEARCH DESIGN AND METHODS</b> - Twelve men with the metabolic syndrome were studied in a randomized double-blind crossover trial of 5-week intervention periods with placebo, 10 mg rosuvastatin, or 40 mg rosuvastatin, with 2-week placebo washouts between each period. VLDL apoC-III kinetics were examined using a stable isotope method and compartmental modeling at the end of each intervention period.</p><p> <b>RESULTS</b> - Compared with placebo, there was a significant dose-dependent reduction with rosuvastatin in plasma triglyceride and VLDL apoC-III concentrations. Rosuvastatin significantly (<I>P</I> < 0.05) increased VLDL apoC-III fractional catabolic rate (FCR) and decreased its production rate, with a significant (<I>P</I> < 0.05) dose-related effect. With 40 mg rosuvastatin, changes in VLDL apoC-III concentration were inversely associated with changes in VLDL apoC-III FCR and positively associated with VLDL apoC-III production rate (<I>P</I> < 0.05). Changes in VLDL apoC-III concentration and production rate were positively correlated with changes in VLDL apoB concentration and production rate and inversely correlated with VLDL apoB FCR (<I>P</I> < 0.05). Similar associations were observed with 10 mg rosuvastatin but were either less or not statistically significant.</p><p> <b>CONCLUSIONS</b> - In this study, rosuvastatin decreased the production and increased the catabolism of VLDL apoC-III, a mechanism that accounted for the significant reduction in VLDL apoC-III and triglyceride concentrations. This has implications for the management of cardiometabolic risk in obese subjects with the metabolic syndrome.</p><p></p> | en |
dc.language | en | en |
dc.publisher | American Diabetes Association | en |
dc.relation.ispartof | Diabetes Care | en |
dc.rights | Attribution-NonCommercial-NoDerivs 3.0 Unported | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/ | * |
dc.title | Dose-Dependent Effect of Rosuvastatin on VLDL-Apolipoprotein C-III Kinetics in the Metabolic Syndrome | en |
dc.type | Journal Article | en |
dc.identifier.doi | 10.2337/dc08-0358 | en |
dcterms.accessRights | UNE Green | en |
local.contributor.firstname | Esther M M | en |
local.contributor.firstname | Gerald F | en |
local.contributor.firstname | Dick C | en |
local.contributor.firstname | Meifania M | en |
local.contributor.firstname | Paul J | en |
local.contributor.firstname | Dmitri | en |
local.contributor.firstname | P Hugh R | en |
local.subject.for2008 | 110306 Endocrinology | en |
local.subject.seo2008 | 920103 Cardiovascular System and Diseases | en |
local.profile.school | Faculty of Medicine and Health | en |
local.profile.email | pbarret6@une.edu.au | en |
local.output.category | C1 | en |
local.record.place | au | en |
local.record.institution | University of New England | en |
local.publisher.place | United States of America | en |
local.format.startpage | 1656 | en |
local.format.endpage | 1661 | en |
local.identifier.scopusid | 49649124713 | en |
local.peerreviewed | Yes | en |
local.identifier.volume | 31 | en |
local.identifier.issue | 8 | en |
local.access.fulltext | Yes | en |
local.contributor.lastname | Ooi | en |
local.contributor.lastname | Watts | en |
local.contributor.lastname | Chan | en |
local.contributor.lastname | Chen | en |
local.contributor.lastname | Nestel | en |
local.contributor.lastname | Sviridov | en |
local.contributor.lastname | Barrett | en |
dc.identifier.staff | une-id:pbarret6 | en |
local.profile.orcid | 0000-0003-3223-6125 | en |
local.profile.role | author | en |
local.profile.role | author | en |
local.profile.role | author | en |
local.profile.role | author | en |
local.profile.role | author | en |
local.profile.role | author | en |
local.profile.role | author | en |
local.identifier.unepublicationid | une:1959.11/30649 | en |
local.date.onlineversion | 2008-05-28 | - |
dc.identifier.academiclevel | Academic | en |
dc.identifier.academiclevel | Academic | en |
dc.identifier.academiclevel | Academic | en |
dc.identifier.academiclevel | Academic | en |
dc.identifier.academiclevel | Academic | en |
dc.identifier.academiclevel | Academic | en |
dc.identifier.academiclevel | Academic | en |
local.title.maintitle | Dose-Dependent Effect of Rosuvastatin on VLDL-Apolipoprotein C-III Kinetics in the Metabolic Syndrome | en |
local.relation.fundingsourcenote | This study was funded by research grants from the National Heart Foundation of Australia and the Raine Medical Research Foundation. E.M.M.O. is a Research Fellow of the National Heart Foundation of Australia (PF 07P 3263). P.H.R.B. and D.S. are research fellows of the National Health and Medical Research Council (NHMRC) and P.H.R.B. was supported in part by the National Institutes of Health (NIH/NIBIB P41 EB-001975). D.C.C. was supported by an NHMRC Career Development Award. | en |
local.output.categorydescription | C1 Refereed Article in a Scholarly Journal | en |
local.search.author | Ooi, Esther M M | en |
local.search.author | Watts, Gerald F | en |
local.search.author | Chan, Dick C | en |
local.search.author | Chen, Meifania M | en |
local.search.author | Nestel, Paul J | en |
local.search.author | Sviridov, Dmitri | en |
local.search.author | Barrett, P Hugh R | en |
local.open.fileurl | https://rune.une.edu.au/web/retrieve/31d1c782-1416-4c3d-9b69-c8c935ce3f85 | en |
local.istranslated | No | en |
local.uneassociation | No | en |
local.atsiresearch | No | en |
local.sensitive.cultural | No | en |
local.year.available | 2008 | en |
local.year.published | 2008 | en |
local.fileurl.open | https://rune.une.edu.au/web/retrieve/31d1c782-1416-4c3d-9b69-c8c935ce3f85 | en |
local.fileurl.openpublished | https://rune.une.edu.au/web/retrieve/31d1c782-1416-4c3d-9b69-c8c935ce3f85 | en |
Appears in Collections: | Journal Article |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
openpublished/DoseDependentBarrett2008JournalArticle.pdf | Published version | 113.38 kB | Adobe PDF Download Adobe | View/Open |
SCOPUSTM
Citations
33
checked on May 25, 2024
Page view(s)
1,062
checked on May 5, 2024
Download(s)
82
checked on May 5, 2024
This item is licensed under a Creative Commons License